TOP - August 2017, Vol 10, No 3

According to the re­sults of a recent survey of hematopoietic stem-cell transplantation (HSCT) professionals, burnout is prevalent across all HSCT disciplines, with pharmacists showing the highest rates of burnout and moral distress. Read Bio ›

The overtreatment or undertreatment of patients with cancer can have life-or-death implications. Read Bio ›

Innovation takes time, especially when it comes to cancer research. However, delays in the adoption of novel oncology treatments can have a significant impact on patient health. Read Bio ›

Over­whelming evidence supports a chemo­preventive benefit of aspirin on colorectal cancer (CRC), and a potential effect on other cancers and cardiovascular risk. Read Bio ›

Enzalutamide did not increase the rate of seizures in men with metastatic castration-resistant prostate cancer (mCRPC) who had potential risk factors for seizure, according to results of the phase 4 UPWARD trial. Read Bio ›

Washington, DC—The combination of nivolumab plus ipilimumab improved survival compared with ipilimumab alone in patients with previously untreated advanced melanoma, according to updated results of the phase 3 CheckMate-067 clinical trial presented at the 2017 meeting of the American Association for Cancer Research. A descriptive analysis suggested that the combination was superior to nivolumab monotherapy, although that was not a prespecified end point of the study. Read Bio ›

As new drugs are introduced into the clinic, an active area of research is the identification of biomarkers for response that would inform oncologists about which patients are likely to respond. Read Bio ›

Abemaciclib, a cyclin-dependent kinase (CDK)4/6 inhibitor, achieved an objective response in 1 of 5 heavily pretreated patients with metastatic hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer. Read Bio ›

Somatostatin analogs have multiple roles in the treatment of neuroendocrine tumors (NETs), including the management of symptoms of hormone hypersecretion and, more recently, slowing tumor progression. Read Bio ›